Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Allurar gwaji don yaƙi da ƙwayar cutar Zika da sauro ke yadawa. Kamuwa ga mata masu ciki yana haifar da ƙanƙantar kai da sauran lahani na jijiya a cikin tayin. A halin yanzu babu allurar da aka amince da ita.
Allurar gwaji don yaƙi da ƙwayar cutar Zika da sauro ke yadawa. Kamuwa ga mata masu ciki yana haifar da ƙanƙantar kai da sauran lahani na jijiya a cikin tayin. A halin yanzu babu allurar da aka amince da ita.
A halin yanzu babu allurar da aka amince da ita. Allurar da ake gwadawa suna a matakin gwaje-gwajen asibiti.
Investigational — specific contraindications will depend on the platform approved. General expectations: mRNA and inactivated candidates expected to have fewer contraindications. Any future live attenuated candidates would be contraindicated in pregnancy and immunocompromised. All candidates: severe allergy to components.
Investigational. Phase 1/2 data: VRC-ZKADNA090: injection site pain (~50%), fatigue, headache, myalgia — generally mild and self-limiting. mRNA-1893: injection site pain (56–78%), fatigue (30–40%), headache (25–35%), myalgia (20%). ZPIV: injection site pain (35%), fatigue, headache. No serious adverse events attributed to any candidate in published trials.
VRC-ZKADNA090 (DNA): 89% seroconversion, neutralizing titers ~1:100 (PRNT50). mRNA-1893: 94% seroconversion after 2 doses, higher GMT than DNA candidate. ZPIV: 92% seroconversion but requires alum adjuvant. No efficacy trials against clinical disease completed (low incidence post-2016 prevents traditional phase 3 trials — adaptive designs under consideration).
Investigational. Co-administration studies planned but limited data. Theoretical considerations: mRNA/inactivated platforms expected to be co-administrable with routine vaccines. Live attenuated: standard 28-day spacing with other live vaccines.
Key target population: women of childbearing age due to congenital Zika syndrome. mRNA and inactivated candidates expected to be safe in pregnancy (but no data yet). Live attenuated candidates: expected contraindication in pregnancy. Pre-conception vaccination strategy likely to be recommended.
No licensed vaccine available as of 2026. Prevention relies on mosquito avoidance (DEET, permethrin-treated clothing, bed nets), sexual transmission prevention (condoms for 3 months after travel for both sexes — CDC; conception timing: wait 3 months for men, 2 months for women after symptom onset/travel), and travel avoidance for pregnant women. WHO maintains Zika virus in R&D Blueprint priority list. Clinical development slowed post-2016 epidemic due to declining incidence making efficacy trials challenging.
Babu bayanan jadawali.
Kun san allurar rigakafin da kuke bukata? Da kyau. Ba ku sani ba? Ku gaya mana inda kuke tafiya — za mu nemo allurar da ta dace da asibiti. Kyauta, ba tare da wani hakki ba.
Abun ciki a wannan shafin don bayani da ilimi ne kawai. Ba ya zama shawarar likita, gano cuta, ko shawarwarin magani ba. Idan kuna da damuwar lafiya, tuntuɓi ƙwararren ma’aikacin lafiya. Medova ba mai ba da sabis na likitanci ba ne.
Cikakkun sharuɗɗan amfani